3//SEC Filing
Pivotal bioVenture Partners Fund I, L.P. 3
Accession 0001012975-20-000661
CIK 0001693011other
Filed
Jul 22, 8:00 PM ET
Accepted
Jul 23, 9:06 PM ET
Size
9.1 KB
Accession
0001012975-20-000661
Insider Transaction Report
Form 3
Holdings
- (indirect: See footnote)
Series A-2 Convertible Preferred Stock
→ Common Stock (1,403,654 underlying)
Holdings
- (indirect: See footnote)
Series A-2 Convertible Preferred Stock
→ Common Stock (1,403,654 underlying)
Holdings
- (indirect: See footnote)
Series A-2 Convertible Preferred Stock
→ Common Stock (1,403,654 underlying)
Footnotes (2)
- [F1]The Series A-2 Convertible Preferred Stock is convertible into Common Stock on a 7.4730-for-1 basis into the number of shares of Common Stock as shown in Column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
- [F2]The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner"). Robert Hopfner, Vincent Cheung, Peter Bisgaard, and Heather Preston are the managing partners of Pivotal's investment advisor and may be deemed to have shared voting and dispositive power over the securities owned by Pivotal. Such persons disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.
Documents
Issuer
Inozyme Pharma, Inc.
CIK 0001693011
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001695076
Filing Metadata
- Form type
- 3
- Filed
- Jul 22, 8:00 PM ET
- Accepted
- Jul 23, 9:06 PM ET
- Size
- 9.1 KB